The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.
 
April A. N. Rose
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; EMD Serono
Research Funding - AstraZeneca Canada (Inst); Canada Foundation for Innovation; Canadian Cancer Society; Canadian Institutes of Health Research (CIHR); Conquer Cancer Foundation; Jewish General Hospital Foundation; Merck (Inst); Pfizer (Inst); Seagen (Inst); TransMedTech Institute
 
Jennifer Maxwell
No Relationships to Disclose
 
Emmanuelle Rousselle
No Relationships to Disclose
 
Melody Riaud
No Relationships to Disclose
 
Chantal Tobin
No Relationships to Disclose
 
Meghan Mcguire
No Relationships to Disclose
 
Ian King
Employment - GenDx; University Health Network
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - 2% share of royalties from licensing of LSC17 leukemia stemness profiling assay.
 
Tong Zhang
No Relationships to Disclose
 
Zaid Saeed Kamil
No Relationships to Disclose
 
Trevor J. Pugh
No Relationships to Disclose
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche; Sanofi
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Philippe L. Bedard
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); LegoChem Biosciences (Inst); LegoChem Biosciences (Inst); Lilly (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen Oncology; Lilly; Repare Therapeutics; Roche/Genentech; Seagen; Zymeworks
 
Natasha B. Leighl
Honoraria - Beigene; BMS; Janssen; MSD Oncology; Takeda
Research Funding - AstraZeneca Canada (Inst); Inivata/NeoGenomics (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Inhibrx; Medison
Research Funding - 23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
Samuel Saibil
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Immunocore; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
David W. Cescon
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai; Gilead Sciences; GlaxoSmithKline; INFLEX; Lilly; Merck; Novartis; Pfizer; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Inivata (Inst); Knight Therapeutics (Inst); Merck (Inst); Pfizer (Inst); ProteinQure (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.
Expert Testimony - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Inivata
 
Anna Spreafico
Honoraria - Immunocore
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Medison; Merck
Research Funding - Alentis Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Surface Oncology (Inst); Symphogen (Inst); Treadwell Therapeutics (Inst)